Cidara Therapeutics completed a $402.5 million public offering to fund its Cloudbreak platform for developing drug-Fc conjugates. Ionis Pharmaceuticals and Biogen reported positive Phase 1 results for salanersen, an antisense oligonucleotide targeting spinal muscular atrophy with potentially greater potency than nusinersen, advancing toward registrational studies.